Retrieve available abstracts of 61 articles: HTML format
Single Articles
May 2025
GIRARD N, Xu Q, Camidge DR, Baijal S, et al Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous
non-small cell lung cancer: pooled analysis from project LUMINATE-101.
Oncologist. 2025;30:oyaf029. PubMedAbstract available
LIN VTG, Ma E, Jain N, Xia Z, et al A rising tide lifts all boats in the personalized cancer care continuum for
mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
Oncologist. 2025;30:oyaf067. PubMedAbstract available
XING P, Pu X, Zhou Y, Liu Z, et al Efficacy and safety of dacomitinib in treatment-naive patients with advanced
NSCLC and brain metastasis: a multicenter cohort study.
Oncologist. 2025;30:oyaf079. PubMedAbstract available
HU X, Melson JW, Pan SS, Salei YV, et al Palliative and end-of-life care in Asian and White patients with metastatic lung
cancer.
Oncologist. 2025;30:oyaf065. PubMedAbstract available
April 2025
BAUTISTA-GONZALEZ E, Munoz Rocha TV, Soto-Perez-de-Celis E, Vindrola-Padros C, et al Treatment delays in patients with lung cancer: a retrospective study conducted at
the National Cancer Institute of Mexico between 2004 and 2021.
Oncologist. 2025;30:oyae358. PubMedAbstract available
March 2025
PENAULT-LLORCA F, Socinski MA Emerging molecular testing paradigms in non-small cell lung cancer
management-current perspectives and recommendations.
Oncologist. 2025 Mar 24:oyae357. doi: 10.1093. PubMedAbstract available
LEVI A, Blais E, Davelaar J, Ebia MI, et al Clinical outcomes and molecular characteristics of lung-only and liver-only
metastatic pancreatic cancer: results from a real-world evidence database.
Oncologist. 2025;30:oyaf007. PubMedAbstract available
GRAY Z, Levonyak N, Jia L, Ahn R, et al Managing elderly patients with dual metastatic cancers-navigating diagnostic and
treatment challenges.
Oncologist. 2025;30:oyaf026. PubMedAbstract available
VITALE A, Vita E, Stefani A, Cancellieri A, et al Overcoming amplification-mediated resistance to sotorasib by dose re-escalation
in KRAS G12C mutant NSCLC: a case report.
Oncologist. 2025;30:oyaf030. PubMedAbstract available
LI Y, Li C, Zhao X, Li Y, et al Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with
EGFR exon 19 deletion or exon 21 L858R: a phase II trial.
Oncologist. 2025;30:oyae336. PubMedAbstract available
VON ITZSTEIN MS, Rashdan S, Dahlberg SE, Gerber DE, et al Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy
in patients with lung cancer.
Oncologist. 2025;30:oyaf036. PubMedAbstract available
RADWAN A, Jani CT, Al Omari O, Patel M, et al The impact of immune-related adverse events on survival outcomes in a racially
diverse population, with a focus on non-Hispanic Black patients.
Oncologist. 2025;30:oyae279. PubMedAbstract available
February 2025
LEITE DA SILVA LF, Saldanha EF, de Menezes JSA, Halamy Pereira L, et al Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced
non-small cell lung cancer: a systematic review and meta-analysis.
Oncologist. 2025;30:oyae344. PubMedAbstract available
SALDANHA EF, Cordeiro de Lima VC, Fares A, Corassa M, et al Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American
patients (CLICaP).
Oncologist. 2025;30:oyae347. PubMedAbstract available
RESTIVO L, Rochigneux P, Bouhnik AD, Arciszewski T, et al Patients' psychosocial attributes and aggressiveness of cancer treatments near
the end of life.
Oncologist. 2025;30:oyae317. PubMedAbstract available
January 2025
SKOULIDIS F, Li BT, Hochmair M, Govindan R, et al Pooled safety analysis and management of sotorasib-related adverse events in KRAS
G12C-mutated advanced non-small cell lung cancer.
Oncologist. 2025;30:oyae356. PubMedAbstract available
ARNDT A, Neumann C, Riecke A, Bauer A, et al Molecular tumor board: molecularly adjusted therapy upon identification and
functional validation of a novel ALK resistance mutation in a case of lung
adenocarcinoma.
Oncologist. 2025;30:oyae143. PubMedAbstract available
December 2024
MEHLMAN C, Swalduz A, Monnet I, Morin C, et al COMPOSIT study: evaluating osimertinib combination with targeted therapies in
EGFR-mutated non-small cell lung cancer.
Oncologist. 2024 Dec 26:oyae312. doi: 10.1093. PubMedAbstract available
CHEN LN, Ma X, Herzberg B, Henick BS, et al Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell
lung cancer.
Oncologist. 2024 Dec 19:oyae315. doi: 10.1093. PubMedAbstract available
LEE HJ JR, Boscardin J, Walter LC, Smith AK, et al Associations of frailty with survival, hospitalization, functional decline, and
toxicity among older adults with advanced non-small cell lung cancer.
Oncologist. 2024 Dec 9:oyae349. doi: 10.1093. PubMedAbstract available
November 2024
NAIDOO J, Johnson DB, Doran C, Wang Y, et al Management of severe immune-related adverse events and outcomes in patients with
advanced non-small cell lung cancer receiving immune checkpoint inhibitors.
Oncologist. 2024 Nov 20:oyae318. doi: 10.1093. PubMedAbstract available
SADAGOPAN N, Komlodi-Pasztor E, Veytsman I Immunotherapy benefits for large brain metastases in non-small cell lung cancer.
Oncologist. 2024 Nov 15:oyae314. doi: 10.1093. PubMedAbstract available
October 2024
ARRIETA O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda LA, et al Evaluation of a risk-sharing agreement for atezolizumab treatment in patients
with non-small cell lung cancer: a strategy to improve access in low-income
countries.
Oncologist. 2024 Oct 19:oyae272. doi: 10.1093. PubMedAbstract available
CAVAGNA RO, Escremim de Paula F, Berardinelli GN, Bonatelli M, et al Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients
who have never smoked: implications for targeted therapies.
Oncologist. 2024;29:e1419-e1424. PubMedAbstract available
September 2024
SHAW J, Pundole X, Balasubramanian A, Anderson ES, et al Recent treatment patterns and real-world survival following first-line anti-PD-L1
treatment for extensive-stage small cell lung cancer.
Oncologist. 2024 Sep 30:oyae234. doi: 10.1093. PubMedAbstract available
APTER L, Sharman Moser S, Gazit S, Chodick G, et al Healthcare resource utilization and associated cost in patients with metastatic
non-small cell lung cancer treated in the immunotherapy era.
Oncologist. 2024 Sep 28:oyae240. doi: 10.1093. PubMedAbstract available
SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al The association of azole antifungals with overall survival in patients with
non-small cell lung cancer receiving immune checkpoint inhibitors.
Oncologist. 2024 Sep 25:oyae262. doi: 10.1093. PubMedAbstract available
Correction to: Homeopathic Treatment as an Add-On Therapy May Improve Quality of
Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A
Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter
Study.
Oncologist. 2024 Sep 24:oyae253. doi: 10.1093. PubMed
ALVES DE SOUZA G, Dornellas DMS, Campregher PV, Teixeira CHA, et al Complete response to capmatinib in a patient with metastatic lung adenocarcinoma
harboring CD47-MET fusion: a case report.
Oncologist. 2024;29:764-767. PubMedAbstract available
FLOREZ N, Patel SP, Wakelee H, Bazhenova L, et al Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Oncologist. 2024 Sep 5:oyae228. doi: 10.1093. PubMedAbstract available
August 2024
DHAWALE TM, Bhat RS, Johnson PC, Srikonda S, et al Telemedicine-based serious illness conversations, healthcare utilization, and end
of life care among patients with advanced lung cancer.
Oncologist. 2024 Aug 29:oyae216. doi: 10.1093. PubMedAbstract available
BOULANGER MC, Schneider JL, Lin JJ Advances and future directions in ROS1 fusion-positive lung cancer.
Oncologist. 2024 Aug 23:oyae205. doi: 10.1093. PubMedAbstract available
MACK PC, Keller-Evans RB, Li G, Lofgren KT, et al Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling
Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Oncologist. 2024;29:e984-e996. PubMedAbstract available
July 2024
FALADE A, Zubiri L, Wu CY, Perlman K, et al Immune-related adverse events requiring hospitalization in patients with lung
cancer: implications and insights.
Oncologist. 2024 Jul 26:oyae189. doi: 10.1093. PubMedAbstract available
MEYER ML, Hirsch FR, Bunn PA, Ujhazy P, et al Calls to action on lung cancer management and research.
Oncologist. 2024 Jul 13:oyae169. doi: 10.1093. PubMedAbstract available
MEHTA GU, Vellanki PJ, Ren Y, Amatya AK, et al FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or
metastatic non-small cell lung cancer with activating HER2 mutations.
Oncologist. 2024 Jul 6:oyae151. doi: 10.1093. PubMedAbstract available
CHANG AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, et al The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and
chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Oncologist. 2024;29:609-618. PubMedAbstract available
CHENG W, Xu T, Yang L, Yan N, et al Dramatic response to crizotinib through MET phosphorylation inhibition in rare
TFG-MET fusion advanced squamous cell lung cancer.
Oncologist. 2024 Jul 2:oyae166. doi: 10.1093. PubMedAbstract available
June 2024
JAYAKRISHNAN R, Kwiatkowski DJ, Rose MG, Nassar AH, et al Topography of mutational signatures in non-small cell lung cancer: emerging
concepts, clinical applications, and limitations.
Oncologist. 2024 Jun 22:oyae091. doi: 10.1093. PubMedAbstract available
NEAL JW, Minichiello K, Brennick R, Huang RSP, et al A process to reanalyze clinical DNA sequencing data for biomarker matching in the
Lung-MAP Master Protocol.
Oncologist. 2024;29:e843-e847. PubMedAbstract available
May 2024
VALLEJO J, Singh H, Larkins E, Drezner N, et al Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in
Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
Oncologist. 2024;29:422-430. PubMedAbstract available
April 2024
CHEN HW, Kuo YW, Chen CY, Chang CH, et al Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint
Inhibitor-Based Therapy.
Oncologist. 2024;29:e498-e506. PubMedAbstract available
ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al Feasibility and User Experience of Digital Patient Monitoring for Real-World
Patients With Lung or Breast Cancer.
Oncologist. 2024;29:e561-e569. PubMedAbstract available
ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small
Cell Lung Cancer: The PACO Randomized Clinical Trial.
Oncologist. 2024 Apr 1:oyae050. doi: 10.1093. PubMedAbstract available
March 2024
XU Y, Ji H, Zhang Y, Xiong L, et al Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as
Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
Oncologist. 2024 Mar 25:oyae052. doi: 10.1093. PubMedAbstract available
PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung
Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis
in Real-World.
Oncologist. 2024 Mar 23:oyae043. doi: 10.1093. PubMedAbstract available
XU Y, Wen N, Haddad RI, Sonis ST, et al Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer
With Different Oral Toxicity Profiles.
Oncologist. 2024;29:e382-e391. PubMedAbstract available
February 2024
STRICKER T, Jain N, Ma E, Yu E, et al Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small
Cell Lung Cancer With Actionable Driver Oncogenes.
Oncologist. 2024 Feb 28:oyae022. doi: 10.1093. PubMedAbstract available
BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated
Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb
Trial.
Oncologist. 2024 Feb 20:oyad342. doi: 10.1093. PubMedAbstract available
January 2024
KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined
Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Oncologist. 2024 Jan 18:oyae001. doi: 10.1093. PubMedAbstract available
GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced
Non-small Cell Lung Cancer.
Oncologist. 2024 Jan 11:oyad335. doi: 10.1093. PubMedAbstract available
WANG H, Fan Z, Yang X, Wu Q, et al Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced
Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
Oncologist. 2024 Jan 10:oyad339. doi: 10.1093. PubMedAbstract available
BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of
Multidisciplinary Management in a Real-World Setting.
Oncologist. 2024;29:e118-e130. PubMedAbstract available
HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint
Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Oncologist. 2024;29:e108-e117. PubMedAbstract available
JORDAN J, Maki RG The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate
Toxicity in Randomized Trials of Systemic Cancer Therapy.
Oncologist. 2024;29:67-74. PubMedAbstract available
November 2023
Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and
Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Oncologist. 2023 Nov 24:oyad316. doi: 10.1093. PubMed
STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical
Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
Oncologist. 2023;28:e981-e994. PubMedAbstract available
October 2023
HU X, Melson JW, Pan SS, Salei YV, et al Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung
Cancer.
Oncologist. 2023 Oct 5:oyad272. doi: 10.1093. PubMedAbstract available
SILVERSTEIN J, Wright F, Wang M, Young A, et al Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events
From Checkpoint Inhibitors.
Oncologist. 2023;28:e950-e959. PubMedAbstract available
September 2023
SHANG X, Zhang C, Kong R, Zhao C, et al Construction of a Diagnostic Model for Small Cell Lung Cancer Combining
Metabolomics and Integrated Machine Learning.
Oncologist. 2023 Sep 14:oyad261. doi: 10.1093. PubMedAbstract available
HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes
and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
Oncologist. 2023 Sep 5:oyad245. doi: 10.1093. PubMedAbstract available